- Home
- ADCT vs GFR Comparison
ADCT vs GFR Comparison
Compare ADCT & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- GFR
- Stock Information
- Founded
- ADCT 2011
- GFR 2018
- Country
- ADCT Switzerland
- GFR Canada
- Employees
- ADCT N/A
- GFR N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- GFR
- Sector
- ADCT Health Care
- GFR
- Exchange
- ADCT Nasdaq
- GFR Nasdaq
- Market Cap
- ADCT 380.2M
- GFR 330.9M
- IPO Year
- ADCT 2020
- GFR N/A
- Fundamental
- Price
- ADCT $3.95
- GFR $4.45
- Analyst Decision
- ADCT Strong Buy
- GFR
- Analyst Count
- ADCT 6
- GFR 0
- Target Price
- ADCT $7.60
- GFR N/A
- AVG Volume (30 Days)
- ADCT 860.1K
- GFR 51.7K
- Earning Date
- ADCT 11-10-2025
- GFR 11-03-2025
- Dividend Yield
- ADCT N/A
- GFR N/A
- EPS Growth
- ADCT N/A
- GFR 252.35
- EPS
- ADCT N/A
- GFR 1.37
- Revenue
- ADCT $77,246,000.00
- GFR $506,500,154.00
- Revenue This Year
- ADCT $11.78
- GFR N/A
- Revenue Next Year
- ADCT $4.83
- GFR $3.61
- P/E Ratio
- ADCT N/A
- GFR $3.24
- Revenue Growth
- ADCT 15.73
- GFR N/A
- 52 Week Low
- ADCT $1.05
- GFR $3.81
- 52 Week High
- ADCT $4.80
- GFR $7.95
- Technical
- Relative Strength Index (RSI)
- ADCT 44.05
- GFR 42.16
- Support Level
- ADCT $3.92
- GFR $4.36
- Resistance Level
- ADCT $4.80
- GFR $5.10
- Average True Range (ATR)
- ADCT 0.23
- GFR 0.23
- MACD
- ADCT -0.06
- GFR -0.03
- Stochastic Oscillator
- ADCT 4.32
- GFR 12.16
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.